|
Background: Oxaliplatin is following cisplatin and carboplatin after the third generation platinum anticancer drugs in clinical practice often with a 5 - fluorouracil and leucovorin combination for colorectal cancer, gastric cancer treatment. Oxaliplatin adverse reactions mainly neurotoxicity, gastrointestinal tract, hematopoietic system toxicity and allergic reactions, including allergic reactions are rare. Foreign scholars have been summarized and analyzed using population in Europe and America after oxaliplatin allergic situation, but only a few cases reported in the country. Objective: To analyze the application of an allergic reaction after oxaliplatin and characteristics to explore the occurrence of oxaliplatin allergy clinical features, relevant factors and optimal treatment methods, to provide a reference for clinical medication safety. Methods: A retrospective survey of Qilu Hospital of Shandong University in June 2003 - May 2009 during oxaliplatin allergy cases, gender, age, KPS score, body surface area, past medical history, previous history of drug allergy food, tumor type, pathological, therapeutic purposes, treatment options, before the occurrence of allergies number of cycles administered L-OHP, L-OHP cumulative dose, with or without concurrent other adverse reactions, abnormal test results before chemotherapy, medication allergies occur after time, allergies occurs, symptoms, treatment of allergic reactions, L-OHP again administered allergy incidents from happening again and so the list is registered. And has had an allergic reaction occurs in patients with an allergic reaction occurs randomly selected patients with the same number of cases, the clinical features of these two sets of statistics whether the differences. All data analysis completed by the statistical software SPSS15.0. Results: A total of 49 cases of patients with varying degrees of oxaliplatin allergic reactions, allergy incidence rate of 1.75%. 71% of patients in the medication within 30min after the onset of symptoms, the most common symptoms of allergic respiratory symptoms and skin changes, 80% of allergic reactions were mild (Ⅰ ~ Ⅱ degree). Oxaliplatin allergic reaction occurs, the median number of cycles for the first six cycles, the average cumulative dose (540 ± s157) mg/m2. First occurrence of L-OHP in patients allergic to reapply in 46 cases, the recurrence of allergic reactions in 13 patients, including 3 patients in three different chemotherapy cycles were an allergic reaction. L-OHP re administration, 26 cases of pharmacological preconditioning in patients six cases of allergic reaction occurs again, 20 cases of patients not pretreated, there are seven cases of recurrence of allergic reactions. Conclusions: 1. Previous patients with a history of food allergies than those without a history of allergy patients are more likely when the L-OHP allergic reaction (P lt; 0.05); 2. Allergic reactions in patients with oxaliplatin used again, either before more mild symptoms, the likelihood of recurrence and severity of allergic reactions have increased; 3. Prophylactic antihistamine effects can not be sure (P gt; 0.05), prolonged infusion time may reduce allergic reactions happen again rate; 4. Ⅰ / Ⅱ degree allergic reaction, symptoms may continue after the slow infusion, but Ⅲ / Ⅳ degree of allergic reaction, advocates permanently disabled oxaliplatin.
|